rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + X

This entry refers to a combination regimen containing rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and an unspecified additional agent ("X"). The standard combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone is known as R-CHOP. R-CHOP is a well-established immunochemotherapy regimen used primarily for the treatment of B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (advanced stage), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia[3][2][4]. Each component has a distinct mechanism: - Rituximab is a monoclonal antibody targeting CD20 on B cells. - Cyclophosphamide is an alkylating agent that crosslinks DNA. - Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Vincristine disrupts microtubule formation during mitosis. - Prednisone is a corticosteroid with anti-inflammatory and cytotoxic effects on lymphoid cells. The addition of "X" suggests this regimen includes another drug or agent not specified here. In clinical practice and research settings, modifications to R-CHOP may include adding drugs like etoposide (as in R-EPOCH) or bortezomib (as in VR-CAP)[5][6]. The precise identity of "X" would determine the full profile of this combination.